Dendritic cell-based vaccines in the setting of peripheral blood stem cell transplantation: CD34+ cell-depleted mobilized peripheral blood can serve as a source of potent dendritic cells

Clinical Cancer Research

Volumn 4, Issue 11, 1998, Pages 2709-2716

  Choi, David ^a   Perrin, Michelle ^a   Hoffmann, Sandra ^a   Chang, Alfred E ^a   Ratanatharathorn, Voravit ^b   Uberti, Joseph ^b   McDonagh, Kevin T ^b   Mulé, James J ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 4; TUMOR NECROSIS FACTOR ALPHA; VACCINE;

ADVANCED CANCER; ARTICLE; CELL ADHESION; DENDRITIC CELL; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNIZATION; LEUKAPHERESIS; LYMPHOCYTE PROLIFERATION; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION;

ANTIGENS, CD34; CANCER VACCINES; CELL SEPARATION; CELLS, CULTURED; DENDRITIC CELLS; FEASIBILITY STUDIES; FLOW CYTOMETRY; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNIZATION; LEUKAPHERESIS; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE SUBSETS; NEOPLASMS; PHENOTYPE; TRANSPLANTATION CONDITIONING;

EID: 0031786757     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Steinman, R., and Nussenzweig, M. Dendritic cells: features and functions. Immunol. Rev., 53: 127-147, 1980.
2. Steinman, R. M., Gutchinor, B., Witmer, M. D., and Nussenzweig, M. C. Dendritic cells are principal stimulators of the primary mixed leukocyte reaction in mice. J. Exp. Med., 157: 613-627, 1983.
3. Stingl, G., and Bergstresser, P. R. Dendritic cells: a major story unfolds. Immunol. Today, 16: 330-333, 1995.
4. Geraghty, P. J., Fields, R. C., and Mulé, J. J. Vaccination with tumor-pulsed splenic dendritic cells mediates immunity to poorly-immunogenic tumor. Surg. Forum, 47: 459-461, 1996.
5. Cohen, P. J., Cohen, P. A., Rosenberg, S. A., Katz, S. I., and Mulé, J. J. Murine epidermal Langerhans cells and splenic dendritic cells present tumor-associated antigens to primed T cells. Eur. J. Immunol., 24: 315-319, 1994.
6. + T-cells from mice immunized to syngeneic sarcomas recognize distinct, non-shared tumor antigens. Cancer Res., 54: 1055-1058, 1994.
7. + T cells in culture with maintained antigen specificity. J. Immunother., 14: 242-252, 1993.
8. Mayordomo, J. I., Zorina, Y., Storkus, W. J., Zitvogel, L., Celluzzi, C., Falo, L. D., Melief, C. J., Ildstad, S. T., Kast, W. M., DeLeo, A. B., and Lotze, M. T. Bone marrow-derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic antitumor immunity. Nat. Med., 1: 1297-1302, 1995.
9. Grabbe, S., Beissert, S., Schaw, T., and Granstein, R. D. Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy. Immunol. Today, 6: 117-121, 1995.
10. Flamand, V., Sornasse, T., Thielemans, K., Demanet, C., Bakkus, M., Bazin, H., Thielemans, F., Leo, O., Urbain, J., and Moser, M. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur. J. Immunol., 24: 605-610, 1994.
11. Sallusto, F., and Lanzavecchia, A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/ macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor-α. J. Exp. Med 179: 1109-1118, 1994.
12. Romani, N., Gruner, S., Brang, D., Kämpgen, E., Lenz, A., Trockenbacker, B., Konwalinka, G., Fritsch, P. O., Steinman, R. M., and Schuler, G. Proliferating dendritic cell progenitors in human blood. J. Exp. Med., 180: 83-93, 1994.
13. Grabbe, S., Bruvers, S., Lindgren, A. M., Hosoi, J., Tan, K. C., and Granstein, R. D. Tumor antigen presentation by epidermal antigen-presenting cells in the mouse: modulation by granulocyte-macrophage colony-stimulating factor, tumor necrosis factor a, and ultraviolet radiation. J. Leukoc. Biol., 52: 209-217, 1992.
14. Lotze, M. T. Getting to the source: dendritic cells as therapeutic reagents for the treatment of patients with cancer. Ann. Surg., 226: 1-5, 1997.
15. Morse, M. A., Zhou, L. J., Tedder, T. F., Lyerly, H. K., and Smith, C. Generation of dendritic cells in vitro from peripheral blood mononuclear cells with granulocyte-macrophage-colony-stimulating factor, interleukin-4, and tumor necrosis factor-α for use in cancer immunotherapy. Ann. Surg., 226: 6-16, 1997.
16. Morel, F., Szilvassy, S. J., Travis, M., Chen, B., and Galy, A. Primitive hematopoietic cells in murine bone marrow express the CD34 antigen. Blood, 88: 3774-3784, 1996.
17. Uchida, N., and Weissman, I. L. Searching for hematopoietic stem cells: evidence that Thy-1.1 lo Lin-Sca-1 + cells are the only stem cells in C57BL/Ka-Thy-1.1 bone marrow. J. Exp. Med., 175: 175-184, 1992.
18. Katsanis, E., Xu, Z., Anderson, P. M., Dancisak, B. B., Bausero, M. A., Weisdorf, D. J., Blazar, B. R., and Ochoa, A. C. Short-term ex vivo activation of splenocytes with anti-CD3 plus IL-2 and infusion post-BMT into mice results in in vivo expansion of effector cells with potent anti-lymphoma activity. Bone Marrow Transplant., 14: 563-572, 1994.
19. Slavin, S., Naparstek, E., Nagler, A., Ackerstein, A., Samuel, S., Kapelushnik, J., Brautbar, C., and Or, R. Allogeneic cell therapy with donor peripheral blood cells and recombinant interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 87: 2195-2204, 1996.
20. Kwak, L. W., Pennington, R., and Longo, D. L. Active immunization of murine allogeneic bone marrow transplant donors with B cell tumor-derived idiotype: a strategy for enhancing the specific antitumor effect of marrow grafts. Blood, 87: 3053-3060, 1996.
21. Mackall, C. L., Bare, C. V., Granger, L. A., Sharrow, S. O., Titus, J. A., and Gress, R. E. Thymic-independent T cell regeneration occurs via antigen-driven expansion of peripheral T cells resulting in a repertoire that is limited in diversity and prone to skewing. J. Immunol., 156: 4609-4616, 1996.
22. + T cells in allogeneic bone marrow transplantation recipients. J. Immunol., 157: 5739-5747, 1996.
23. Ridge, J. P., Fuchs, E. J., and Matzinger, P. Neonatal tolerance revisited: turning on newborn T cells with dendritic cells. Science (Washington DC), 271: 1723-1726, 1996.
24. + cells in autologous stem cell transplantation for breast cancer. Blood, 87: 1687-1691, 1996.
25. + T cells in vitro. Blood, 91: 4652-4661, 1998.
26. + dendritic cells. Proc. Natl. Acad. Sci. USA, 93: 2588-2593, 1996.
27. Trizio, D., and Cudkowicz, G. Separation of T and B lymphocytes by nylon wool columns: evaluation of efficacy by functional assays in vivo. J. Immunol., 113: 1093-1097, 1974.
28. Paglia, P., Chiodoni, C., Rodolfo, M., and Colombo, M. P. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J. Exp. Med., 183: 317-322, 1996.
29. Boczkowski, D., Nair, S. K., Snyder, D., and Gilboa, E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J. Exp. Med., 184: 465-472, 1996.
30. Condon, C., Watkins, S. C., Celluzzi, C. M., Thompson, K., and Falo, L. D., Jr. DNA-based immunization by in vivo transfection of dendritic cells. Nat. Med., 2: 1122-1128, 1996.
31. Hsu, F. J., Engleman, E. G., and Levy, R. Dendritic cells and their application in immunotherapeutic approaches to cancer therapy. In: V. T. DeVita, Jr., S. Hellman, and S. A. Rosenberg (eds.), Cancer Principles and Practice of Oncology Updates, Vol. 11, pp. 1-14. Cedar Knolls, NJ: Lippincott-Raven Healthcare, 1997.
32. Tarte, K., Lu, Z. Y., Fiol, G., Legouffe, E., Rossi, J-F., and Klein, B. Generation of virtually pure and potentially proliferating dendritic cells from non-CD34 apheresis cells from patients with multiple myeloma. Blood, 90: 3482-3495, 1997.
33. + precursors. J. Immunol., 158: 2134-2142, 1997.
34. Peoples, G. E., Goedegebuure, P. S., Smith, R., Linehan, D. C., Yoshino, I., and Eberlein, T. J. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc. Natl. Acad. Sci. USA, 92: 432-436, 1995.
35. Tsang, K. Y., Zaremba, S., Nieroda, C. A., Zhu, M. Z., Hamilton, J. M., and Schlom, J. Carcinoembryonic antigen epitopes from patients: immunized with recombinant vaccinia-CEA vaccine. J. Natl. Cancer Inst., 87: 982-990, 1995.
36. Cooper, D. L. Peripheral blood stem cell transplantation. In: V. T. DeVita, Jr., S. Hellman, and S. A. Rosenberg (eds.), Cancer Principals and Practice of Oncology Updates, Vol. 8, pp. 1-12. Cedar Knolls, NJ: Lippincott-Raven Healthcare, 1994.
37. Hsu, F. J., Benike, C., Fagnoni, F., Liles, T. M., Czerwinski, D., Taidi, B., Engleman, E. G., and Levy, R. Vaccination of patients with B cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med., 2: 52-55, 1996.
38. Nestle, F. O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G., and Schadendorf, D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med., 4: 328-332, 1998.